Published peptide research protocols span a 500-fold dosing range — from 20mcg of IGF-1 LR3 to 10mg of Epithalon per administration. The variation isn’t random. It reflects differences in receptor binding affinity, half-life, route of administration, and the specific biological endpoint being measured. This reference page compiles dosing data from published studies for all 20 peptides in the PreWorkout Formula catalog.
Critical distinction: the numbers below come from published research literature. They describe what has been used in controlled studies. They are not clinical recommendations or protocols for human use outside formal research settings.
For research use only. Not for human consumption.
Concentration and Volume Calculations
Before any dosing, you need two numbers: the concentration of your reconstituted solution and the volume that delivers your target dose.
Concentration = Peptide mass (mg) / Solvent volume (mL)
Dose volume = Target dose (mcg) / Concentration (mcg/mL)
Standard reconstitution scenarios:
| Vial | Solvent | Concentration | 100mcg = | 250mcg = | 500mcg = |
|---|---|---|---|---|---|
| 2mg | 1mL | 2,000mcg/mL | 5 units | 12.5 units | 25 units |
| 2mg | 2mL | 1,000mcg/mL | 10 units | 25 units | 50 units |
| 5mg | 1mL | 5,000mcg/mL | 2 units | 5 units | 10 units |
| 5mg | 2mL | 2,500mcg/mL | 4 units | 10 units | 20 units |
| 10mg | 2mL | 5,000mcg/mL | 2 units | 5 units | 10 units |
| 10mg | 5mL | 2,000mcg/mL | 5 units | 12.5 units | 25 units |
Units refer to markings on a standard 100-unit (1mL) insulin syringe, where 1 unit = 0.01mL. Pick a reconstitution volume that gives you round syringe numbers for your target dose. This reduces measurement error and makes protocol adherence straightforward.
For detailed reconstitution technique (sidewall method, dissolution tips, storage), see the reconstitution guide.
Complete Dosing Reference by Compound
Healing & Tissue Repair
| Peptide | Published Research Range | Protocol Frequency | Route | Suggested Reconstitution |
|---|---|---|---|---|
| BPC-157 | 200-500mcg per administration | 1-2x daily | SC or oral | 5mg + 2mL BAC = 2,500mcg/mL |
| TB-500 | 2-5mg per administration | 2x/week (loading) then 1x/week | SC | 5mg + 1mL BAC = 5,000mcg/mL |
| GHK-Cu | 1-2mg per administration | Daily or 3x/week | SC or topical | 5mg + 2mL BAC = 2,500mcg/mL |
| KPV | 300-600mcg per administration | 1-2x daily | SC or oral | 5mg + 2mL BAC = 2,500mcg/mL |
| LL-37 | 100-500mcg per administration | Daily or 3x/week | SC | 5mg + 2mL BAC = 2,500mcg/mL |
BPC-157 dosing note: Unlike most research peptides, BPC-157 shows activity via oral administration in animal models. Research protocols split between oral and subcutaneous routes. The published oral doses tend to run higher than subcutaneous doses — consistent with expected GI absorption losses. Some protocols use both routes simultaneously (oral for systemic + local SC injection near injury site).
TB-500 loading protocol: The 2x/week loading phase typically runs 4-6 weeks in published protocols before transitioning to 1x/week maintenance. The front-loaded approach saturates the actin-binding mechanism before dropping to a maintenance frequency.
Growth Hormone Secretagogues & Anabolic Peptides
| Peptide | Published Research Range | Protocol Frequency | Timing Notes | Suggested Reconstitution |
|---|---|---|---|---|
| CJC-1295 (no DAC) | 100-200mcg | 1x daily (pulsatile) | Pre-sleep in most protocols | 2mg + 2mL = 1,000mcg/mL |
| Ipamorelin | 200-300mcg | 1-2x daily | Pre-sleep and/or AM fasted | 2mg + 2mL = 1,000mcg/mL |
| CJC-1295/Ipamorelin Blend | 100-200mcg per component | 1-2x daily | Combined pulse timing | Per blend ratio on COA |
| GHRP-6 | 100-300mcg | 2-3x daily (pulsed) | Fasted state for max GH output | 5mg + 2mL = 2,500mcg/mL |
| Sermorelin | 200-500mcg | 1x daily | Pre-sleep (bedtime dosing in studies) | 5mg + 2mL = 2,500mcg/mL |
| IGF-1 LR3 | 20-50mcg | 1x daily | Post-exercise in some protocols | 1mg + 2mL = 500mcg/mL |
| AOD-9604 | 300-500mcg | 1x daily | AM fasted in metabolic studies | 5mg + 2mL = 2,500mcg/mL |
Pulsatile timing matters for GH peptides. The pituitary releases growth hormone in discrete pulses — the largest occurring 1-2 hours after sleep onset. GH secretagogues amplify these natural pulses. Most published research protocols schedule administration to align with endogenous GH rhythms: pre-sleep dosing, fasted morning dosing, or both. Continuous GH elevation (as seen with CJC-1295 + DAC) can desensitize pituitary receptors over time. Pulsatile protocols avoid this.
IGF-1 LR3 is not a secretagogue. It’s a direct IGF-1 receptor agonist with a ~20-hour half-life (native IGF-1 half-life: ~15 minutes). The dose range is significantly lower than GH secretagogues because it bypasses the pituitary entirely. Doses above 50mcg are associated with insulin-like hypoglycemic effects in published data — this is a dose-sensitive compound.
Anti-Aging & Longevity
| Peptide | Published Research Range | Protocol Structure | Duration | Suggested Reconstitution |
|---|---|---|---|---|
| Epithalon | 5-10mg daily | Cyclic: daily during on-phase | 10-20 days on, 3-6 months off | 10mg + 2mL = 5,000mcg/mL |
Epithalon’s cyclic protocol originates from Professor Vladimir Khavinson’s research at the St. Petersburg Institute of Bioregulation and Gerontology. The 10-20 day administration cycles with multi-month intervals between cycles reflect the compound’s proposed mechanism — triggering telomerase activation that persists beyond the administration period. Continuous dosing is not used in the published protocols.
GHK-Cu and Thymosin Alpha 1 dosing appears in the Healing and Immune sections respectively, as those reflect their primary research applications. Both also appear in anti-aging research — refer to those sections for dosing data.
Nootropic & Neuroprotective
| Peptide | Published Research Range | Protocol Frequency | Route | Suggested Reconstitution |
|---|---|---|---|---|
| Semax | 200-600mcg | 1-2x daily | Intranasal or SC | 5mg + 5mL = 1,000mcg/mL |
| Selank | 250-500mcg | 1-2x daily | Intranasal or SC | 5mg + 5mL = 1,000mcg/mL |
| DSIP | 100-300mcg | 1x daily (evening) | SC or IV in studies | 2mg + 2mL = 1,000mcg/mL |
Route matters for Semax and Selank. The Russian clinical literature uses intranasal delivery almost exclusively — this route allows a fraction of the dose to reach the CNS directly via olfactory nerve pathways, bypassing the blood-brain barrier. Subcutaneous delivery provides systemic exposure but without the direct CNS access. For intranasal protocols, reconstitute with sterile saline (0.9% NaCl) rather than BAC water — benzyl alcohol is a mucosal irritant.
DSIP’s delta-wave sleep effects are observed at relatively low doses. The compound is a nonapeptide that crosses the blood-brain barrier, which is uncommon among peptides. Evening dosing aligns with the target endpoint (sleep architecture modification). Daytime administration produces sedation as an expected pharmacological effect.
Immune Modulation
| Peptide | Published Research Range | Protocol Frequency | Clinical Reference | Suggested Reconstitution |
|---|---|---|---|---|
| Thymosin Alpha 1 | 1.0-1.6mg | 2x/week | Zadaxin approved dose: 1.6mg SC 2x/week | 1.6mg + 1mL = 1,600mcg/mL |
Thymosin Alpha 1 has the most standardized dosing protocol of any research peptide. The 1.6mg twice-weekly subcutaneous regimen is the approved clinical dose in 35+ countries where it’s marketed as Zadaxin. Research protocols overwhelmingly mirror this schedule. The twice-weekly frequency matches the compound’s mechanism — driving T-cell maturation and dendritic cell activation through processes that don’t require daily stimulation.
LL-37 and KPV dosing data appears in the Healing section above, as tissue repair and anti-inflammatory applications overlap with immune modulation research.
Sexual Health & Melanocortin
| Peptide | Published Research Range | Protocol Structure | Key Consideration | Suggested Reconstitution |
|---|---|---|---|---|
| PT-141 | 1-2mg per dose | As-needed (single dose) | Nausea increases sharply above 2mg | 10mg + 2mL = 5,000mcg/mL |
| Melanotan II | 250-500mcg | Daily loading, then maintenance | Start low — nausea is dose-dependent | 10mg + 2mL = 5,000mcg/mL |
| Kisspeptin | 1-10mcg/kg body weight | Pulsatile, protocol-dependent | Weight-based dosing standard | 1mg + 2mL = 500mcg/mL |
PT-141 vs. Melanotan II — different protocols entirely. PT-141 is acute: single administration 45-60 minutes before the target research endpoint. The FDA-approved Vyleesi dose is 1.75mg subcutaneous. Nausea incidence in clinical trials was 40% at standard doses and escalates above 2mg without proportional efficacy gains.
Melanotan II requires a loading phase. Melanogenesis effects accumulate over multiple administrations — typically starting at 250mcg or less and titrating upward over 1-2 weeks. The broader melanocortin receptor profile (MC1R through MC5R) means a wider effect spectrum than PT-141, including skin pigmentation changes that can persist weeks after discontinuation.
Kisspeptin dosing is weight-based in published literature, expressed in mcg/kg. The pulsatile administration schedules in research reflect its physiological role — kisspeptin drives pulsatile GnRH release from the hypothalamus, which in turn drives pulsatile LH and FSH secretion.
Storage Quick Reference
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized (sealed) | 2-8 degrees C | 12-24 months | Away from light, sealed vial |
| Lyophilized (sealed) | -20 degrees C | 2+ years | Extended storage |
| Reconstituted (BAC water) | 2-8 degrees C | 28-30 days | Label with date and concentration |
| Reconstituted (aliquoted) | -20 degrees C | 3-6 months | Single thaw per aliquot — never refreeze |
Compound-specific sensitivity: GHK-Cu is oxidation-prone — refrigerate even in lyophilized form. IGF-1 LR3 benefits from acidified reconstitution solution (0.6% acetic acid) for improved stability.
For step-by-step reconstitution instructions, see How to Reconstitute Peptides. For compound mechanisms and receptor targets, see What Are Peptides? For safety profiles and purity evaluation, see Are Peptides Safe?
Browse the full catalog with independent COA documentation at Peptides for Sale.